Dr Peter Alexander Fedyshin, MD | |
85 Timberland Trl, Arnoldsville, GA 30619-2216 | |
(412) 330-7206 | |
Not Available |
Full Name | Dr Peter Alexander Fedyshin |
---|---|
Gender | Male |
Speciality | Emergency Medicine |
Location | 85 Timberland Trl, Arnoldsville, Georgia |
Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
Identifier | Type | State | Issuer |
---|---|---|---|
1174151591 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
207P00000X | Emergency Medicine | 96436 (Georgia) | Primary |
Entity Name | Athens Clarke Medical Enterprises Llc |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1295370542 PECOS PAC ID: 0547698680 Enrollment ID: O20200324000216 |
News Archive
The U.S. Food and Drug Administration today approved Tivicay (dolutegravir), a new drug to treat HIV-1 infection. Tivicay is an integrase strand transfer inhibitor that interferes with one of the enzymes necessary for HIV to multiply.
Bionovo, Inc., a drug discovery and development company focused on unmet needs in women's health and oncology, today announced that it has entered into definitive agreements to raise approximately $3.0 million in gross proceeds in a registered direct offering through the sale of common stock and warrants.
VIVUS, Inc. today announced that data from the previously reported phase 3 pivotal REVIVE (TA-301) study, evaluating the safety and efficacy of the investigational drug avanafil for the treatment of erectile dysfunction (ED), were presented at the American Urological Association (AUA) 2010 Annual Meeting.
CSL Behring announced today that the U.S. Food and Drug Administration (FDA) has granted marketing approval for RiaSTAP(TM), the first and only treatment of acute bleeding episodes in patients with congenital fibrinogen deficiency, including afibrinogenemia and hypofibrinogenemia.
› Verified 8 days ago
Mailing Address | Practice Location Address |
---|---|
Dr Peter Alexander Fedyshin, MD 85 Timberland Trl, Arnoldsville, GA 30619-2216 Ph: (412) 330-7206 | Dr Peter Alexander Fedyshin, MD 85 Timberland Trl, Arnoldsville, GA 30619-2216 Ph: (412) 330-7206 |
News Archive
The U.S. Food and Drug Administration today approved Tivicay (dolutegravir), a new drug to treat HIV-1 infection. Tivicay is an integrase strand transfer inhibitor that interferes with one of the enzymes necessary for HIV to multiply.
Bionovo, Inc., a drug discovery and development company focused on unmet needs in women's health and oncology, today announced that it has entered into definitive agreements to raise approximately $3.0 million in gross proceeds in a registered direct offering through the sale of common stock and warrants.
VIVUS, Inc. today announced that data from the previously reported phase 3 pivotal REVIVE (TA-301) study, evaluating the safety and efficacy of the investigational drug avanafil for the treatment of erectile dysfunction (ED), were presented at the American Urological Association (AUA) 2010 Annual Meeting.
CSL Behring announced today that the U.S. Food and Drug Administration (FDA) has granted marketing approval for RiaSTAP(TM), the first and only treatment of acute bleeding episodes in patients with congenital fibrinogen deficiency, including afibrinogenemia and hypofibrinogenemia.
› Verified 8 days ago